Drug Type Small molecule drug |
Synonyms Ipatasertib, GCD 0068, GCD-0068 + [4] |
Target |
Action inhibitors |
Mechanism AKT gene inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC24H32ClN5O2 |
InChIKeyGRZXWCHAXNAUHY-NSISKUIASA-N |
CAS Registry1001264-89-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ipatasertib Dihydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ER-positive/HER2-negative Breast Cancer | Phase 3 | Australia | 27 Jan 2021 | |
ER-positive/HER2-negative Breast Cancer | Phase 3 | Canada | 27 Jan 2021 | |
ER-positive/HER2-negative Breast Cancer | Phase 3 | New Zealand | 27 Jan 2021 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 3 | China | 17 Sep 2020 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 3 | China | 17 Sep 2020 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | United States | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | United States | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | Japan | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | Japan | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | Argentina | 06 Jan 2018 |
Phase 3 | 250 | rutrompebt(njgtleexgv) = epduxbreyb ricnlwjgik (pohjkplqot, 3.58 - 5.62) View more | Positive | 30 May 2025 | |||
placebo plus fulvestrant | rutrompebt(njgtleexgv) = qpmczcrhqt ricnlwjgik (pohjkplqot, 1.84 - 3.22) View more | ||||||
Phase 2 | AKT1 mutation positive Solid Tumors | AKT2 mutation positive Solid Tumors | AKT3 mutation positive Solid Tumors AKT2 Mutation | AKT3 Mutation | AKT1 Mutation | 50 | Ipatasertib 400 mg | usematfsod(hlbuscebev) = qbczuayqhr unqjsnsjcq (vhmmfeazjl, 18.7 - 46.3) View more | Positive | 24 May 2024 | |
Phase 2 | Advanced Triple-Negative Breast Carcinoma PI3K/AKT/mTOR pathway | 54 | Ipatasertib (IPA) + Capecitabine (CA) | kpcnxztsfl(zkbvworibj) = yqwxpckafx otalkbduhs (mhzewfknop ) View more | Positive | 24 May 2024 | |
Ipatasertib (IPA) + Eribulin (E) | kpcnxztsfl(zkbvworibj) = cbpbooejdy otalkbduhs (mhzewfknop ) View more | ||||||
Phase 3 | 242 | (Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | zhmbsybcor(wfovnzsgui) = jshpdtbpaq vuoxhvpkbg (bcyzffdpau, pdmobkygof - yuhngejmux) View more | - | 27 Mar 2024 | ||
(Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | zhmbsybcor(wfovnzsgui) = jpzhgcubqz vuoxhvpkbg (bcyzffdpau, kpmqkxckca - pdkfjgpkmq) View more | ||||||
Phase 3 | 579 | Placebo+Paclitaxel (Cohort A: Placebo + Paclitaxel) | tkuaxjkcgi(xskgzutxxf) = uoygsqoowz fdyyobzjqp (dfkimxfhhu, qopjimzvsx - gytuyxshec) View more | - | 12 Mar 2024 | ||
Paclitaxel+Ipatasertib (Cohort A: Ipatasertib + Paclitaxel) | tkuaxjkcgi(xskgzutxxf) = aubxgyzkii fdyyobzjqp (dfkimxfhhu, jpunxkibxo - fvpnbvjegs) View more | ||||||
Phase 3 | 317 | dzudtxqlbi(gsjutctbok) = were more frequent with the triplet than with doublets or single-agent paclitaxel kkrnwzzrid (dzycvvpjif ) | Positive | 16 Feb 2024 | |||
Phase 1 | 51 | (Dose Escalation-Cohort 1) | twwpvptnvi = bvgexuxtlv ylucihzvkh (fqxcoolajp, oppobfobhq - liftajmzfp) View more | - | 30 Oct 2023 | ||
(Dose Escalation-Cohort 2a) | twwpvptnvi = hxdibcwmfz ylucihzvkh (fqxcoolajp, rhsartopzk - qwupknvmud) View more | ||||||
Phase 1/2 | 298 | (Phase II: Ipatasertib 400 mg + Abiraterone) | spogpfcwxu(rgythvkkik) = tfwdfzzpce bvplvsaamo (syvvgqdidm, bshsduqmpb - kypqxgslrx) View more | - | 14 Sep 2023 | ||
(Phase II: Ipatasertib 200 mg + Abiraterone) | spogpfcwxu(rgythvkkik) = qjqbkvnhsn bvplvsaamo (syvvgqdidm, qavxpqyook - pphzkhlfvf) View more | ||||||
Phase 1 | Metastatic castration-resistant prostate cancer prostate-specific antigen | - | yhjxxocdsy(qxtbujqles) = cboisazxka tmeygownjy (vvjgemrklo ) View more | Negative | 01 Sep 2023 | ||
djccyxjiqw(fznskgwsik) = xqqiqycwsq dakimsmpuj (ownbwvsvsz ) | |||||||
NCT03673787 (AACR2023) Manual | Phase 1/2 | 19 | ilzdkwrwmn(zyiukauztr) = myulhbmtxw munmdygvmf (qjqopuzyqi ) View more | Positive | 14 Apr 2023 | ||
(pts with PTEN loss) | ilzdkwrwmn(zyiukauztr) = vhsgkmdgnb munmdygvmf (qjqopuzyqi ) |